Fennec Pharmaceuticals Inc
FENC - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$408M
Close$
$-9.11
178.4% downside
Current Fair Value
178.4% downsideOvervalued by 178.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $408.00 Million |
|---|---|
| Enterprise Value | $362.12 Million |
| Earnings per Share | $-0.36 |
| Beta | 1.21 |
| Outstanding Shares | 35,112,000 |
Return
| Return on Equity | 3.23% |
|---|---|
| Return on Assets | 1.90% |
| Return on Invested Capital | 4.98% |
Valuation & Multiples
| P/E Ratio | 507.42 |
|---|---|
| PEG | -61.34 |
| Price to Sales | 11.62 |
| Price to Book Ratio | 11.62 |
| Enterprise Value to Revenue | 5.44 |
| Enterprise Value to EBIT | 103.39 |
| Enterprise Value to Net Income | 227 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 12, 2026
EPS
$0.12
Est. $0.10Revenue
$19.61 M
Est. $18.87 MNext Earnings Call
Expected Date
March 23, 2027
EPS Estimate
$0.15
Consensus analyst estimateRevenue Estimate
$21.46 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.94%▼ 16.50% |
|---|---|
| Total Invested | $113.84M▼ 35.27% |
| Investors Holding | 80▼ 29.00% |
About Fennec Pharmaceuticals Inc
35 employees
CEO: Rostislav Raykov
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation curren...